[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0612248T3 - Præparat, der indeholder cisplatin og topotecan som antitumormiddel - Google Patents

Præparat, der indeholder cisplatin og topotecan som antitumormiddel

Info

Publication number
DK0612248T3
DK0612248T3 DK92925253T DK92925253T DK0612248T3 DK 0612248 T3 DK0612248 T3 DK 0612248T3 DK 92925253 T DK92925253 T DK 92925253T DK 92925253 T DK92925253 T DK 92925253T DK 0612248 T3 DK0612248 T3 DK 0612248T3
Authority
DK
Denmark
Prior art keywords
human
topotecan
composition containing
compound
antitumor agent
Prior art date
Application number
DK92925253T
Other languages
English (en)
Inventor
Randall Keith Johnson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0612248T3 publication Critical patent/DK0612248T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92925253T 1991-11-15 1992-11-13 Præparat, der indeholder cisplatin og topotecan som antitumormiddel DK0612248T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79304191A 1991-11-15 1991-11-15
PCT/US1992/009864 WO1993009782A1 (en) 1991-11-15 1992-11-13 Combination chemotherapy

Publications (1)

Publication Number Publication Date
DK0612248T3 true DK0612248T3 (da) 2003-12-08

Family

ID=25158913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92925253T DK0612248T3 (da) 1991-11-15 1992-11-13 Præparat, der indeholder cisplatin og topotecan som antitumormiddel

Country Status (15)

Country Link
US (1) US5633016A (da)
EP (3) EP0612248B1 (da)
JP (1) JPH07501079A (da)
AT (1) ATE247471T1 (da)
AU (1) AU671605B2 (da)
CA (1) CA2123321C (da)
DE (1) DE69233169T2 (da)
DK (1) DK0612248T3 (da)
ES (1) ES2204894T3 (da)
HK (1) HK1012268A1 (da)
MX (1) MX9206577A (da)
NZ (1) NZ245112A (da)
PT (1) PT101061B (da)
WO (1) WO1993009782A1 (da)
ZA (1) ZA928771B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
EP0612248B1 (en) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.
EP0778024B1 (en) * 1993-01-15 2002-11-13 The Stehlin Foundation For Cancer Research Oral or intramuscular treatment of pancreatic cancer with water-insoluble S-Camptothecin of the closed lactone ring form
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
CA2225682A1 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
EP2269619A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
CA2518150C (en) * 2003-03-03 2015-08-11 Board Of Regents, The University Of Texas System Methods and compositions involving mda-7
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (en) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009099651A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
BR112013017096A2 (pt) 2011-01-04 2020-09-01 Jennerex Inc. composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
WO2013094581A1 (ja) * 2011-12-21 2013-06-27 株式会社ヤクルト本社 新規なカンプトテシン誘導体
EP2794907B2 (en) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
US11091808B2 (en) 2012-06-07 2021-08-17 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
PT2981624T (pt) 2013-04-05 2020-03-23 Myriad Genetics Inc Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro
US9821008B2 (en) * 2013-11-25 2017-11-21 The University Of Toledo Inhibitors of ERCC1-XPF and methods of using the same
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP3686288B1 (en) 2014-08-15 2023-03-08 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
EP0612248B1 (en) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.

Also Published As

Publication number Publication date
MX9206577A (es) 1993-05-01
JPH07501079A (ja) 1995-02-02
CA2123321C (en) 2003-09-30
WO1993009782A1 (en) 1993-05-27
PT101061B (pt) 1999-07-30
HK1012268A1 (en) 1999-07-30
DE69233169T2 (de) 2004-05-27
US5633016A (en) 1997-05-27
CA2123321A1 (en) 1993-05-27
EP0612248A1 (en) 1994-08-31
DE69233169D1 (de) 2003-09-25
ZA928771B (en) 1993-09-08
EP1393730A2 (en) 2004-03-03
ATE247471T1 (de) 2003-09-15
EP1393729A2 (en) 2004-03-03
AU671605B2 (en) 1996-09-05
AU3137993A (en) 1993-06-15
EP1393729A3 (en) 2004-03-17
EP0612248B1 (en) 2003-08-20
ES2204894T3 (es) 2004-05-01
PT101061A (pt) 1994-06-30
EP1393730A3 (en) 2004-03-17
EP0612248A4 (en) 1996-05-08
NZ245112A (en) 1995-07-26

Similar Documents

Publication Publication Date Title
DK0612248T3 (da) Præparat, der indeholder cisplatin og topotecan som antitumormiddel
IL104006A0 (en) Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
IL89840A0 (en) Substituted flavonoid compounds and salts thereof,their preparation and pharmaceutical compositions containing them
IE873125L (en) Benzimidazole derivatives
EP0620004A4 (en) MEDICAL COMPOSITION.
EP0344880A3 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
IL91047A0 (en) Pharmaceutical compositions containing a zinc complex
DE69302838D1 (de) Kosmetische und/oder pharmazeutische Zubereitungen und Verfahren zu ihrer Verwendung zum Schutz der Gewebe vor Kontakt mit Schwermetallen
GR3033253T3 (en) Tri(platinum) complexes
DK166323C (da) Griseolsyrederivater og farmaceutiske midler indeholdende disse
JO1406B1 (en) Chemical compounds
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
IL106289A (en) Phospholipid derivatives their preparation and pharmaceutical compositions containing them
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DE69233793D1 (de) Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs
EP0173145A3 (en) Reduction of the toxic effects caused by anthraquinone drugs
ZA858316B (en) Pyrazine diazohydroxide compounds and methods for production and use
MY105876A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer.
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)